102 results about "Enterobacterales" patented technology

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an LL-37 derived antibacterial peptide and application thereof. According to the invention, 17-29aa of the LL-37 antibacterial peptide is used as a core fragment and is connected with an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 through an amido bond, the antibacterial activity of the obtained antibacterial peptide is obviously higher than that of the LL-37 antibacterial peptide, and the antibacterial peptide shows an obvious bactericidal effect on clinical drug-resistant bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, escherichia coli, staphylococcus aureus, klebsiella pneumoniae and the like; meanwhile, the cytotoxicity and hemolytic activity are weak, drug resistance is not prone to being generated, bacteria can be rapidly killed in vivo through multiple mechanisms, no obvious cytotoxicity exists, the bacterium load in tissue is remarkably reduced, and the lifetime of a bacterium-infected mouse is prolonged.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The invention relates to the technical field of PA resin, and particularly discloses glass fiber modified antibacterial PA resin suitable for children products and a preparation method of the antibacterial PA resin. The invention discloses glass fiber modified antibacterial PA resin suitable for children products. The glass fiber modified antibacterial PA resin comprises PA resin, glass fibers, talcum powder, nano calcium carbonate, a composite antibacterial agent, a compatilizer, an antioxidant and calcium stearate, the composite antibacterial agent comprises chitosan, an antibacterial peptide microcapsule and a porous silver-zinc-loaded antibacterial agent; the antibacterial peptide microcapsules are sodium alginate embedded antibacterial peptides. The antibacterial PA resin obtained in the invention has the highest bacteriostasis rates of 99.97%, 99.74% and 99.95% for staphylococcus aureus, escherichia coli and candida albicans respectively, the antibacterial property of the PA resin is improved, the compressive strength and notch impact strength are 170.6 MPa and 17.3 kJ / m < 2 > respectively, and high mechanical strength is maintained on the basis of high antibacterial property.

The invention relates to the technical field of bioengineering, in particular to a penicillin G acylase mutant, polynucleotide, an expression vector and application. The penicillin G acylase mutant is obtained by carrying out site-directed mutagenesis on a wild type penicillin G acylase gene of parent Escherichia coli, and carrying out site-directed mutagenesis on the wild type penicillin G acylase gene to obtain the penicillin G acylase mutant. Phenylalanine (F) at the 24th site of an alpha chain, proline (P) at the 383rd site of a beta chain, threonine (T) at the 384th site of the beta chain, glutamic acid (G) at the 385th site of the beta chain and serine (S) at the 386th site of the beta chain of the penicillin G acylase are introduced and mutated by a whole plasmid PCR (Polymerase Chain Reaction) technology to obtain mutants. When the penicillin G acylase mutant obtained by the invention is used for catalyzing methyl mandelate and 3-(1-methyl-1H-tetrazole-5-yl) thiomethyl-7-aminocephalosporanic acid to synthesize cefamandole, the synthesis activity is improved, and meanwhile, the side reaction rate is greatly reduced.

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

The present invention relates to the use of a combination of a saccharide and glycerol for skin protection against undesirable bacteria. The present invention is particularly useful in the formulation of compositions that act as prebiotics for commensal skin bacteria such as S. epidermidis to produce metabolites such as lactic acid, which, through the present invention, has been shown to inhibit the growth of undesirable bacteria such as E. coli and S. aureus, among others. The present invention is especially useful because it provides both short-term (i.e., rapid) and long-term (or sustained) protection.

The invention provides a plant fiber containing a ginger extract and a preparation process of the plant fiber. After the plant fiber is washed for 50 times, the bacteriostasis rates of the plant fiber to staphylococcus aureus, escherichia coli, klebsiella pneumoniae and candida albicans are all greater than or equal to 95%, the killing rates of the plant fiber to influenza viruses H3N2 and H1N1 are all greater than or equal to 99%, the far infrared emissivity is 0.89-0.95, the highest temperature rise of moisture absorption and heating is 4-12 DEG C, and the average temperature rise is 3-8 DEG C. A vapor deposition method is adopted, a biomass component A and a biomass component B are combined to form a biomass component C, on one hand, the biomass component B serves as a tube bundle-shaped base material, rhizome plants are calcined to form a porous carbon structure framework, the porous carbon structure framework serves as a solid for vapor deposition, and a solution containing the biomass component A is small in gas molecular weight; after being vaporized along with the solution, the solution is caught by a porous structure of the biomass component B and uniformly filled into pores of the biomass component B, so that the durability of plant functions is ensured, and meanwhile, a protection effect at high temperature is achieved.

The invention belongs to the technical field of microbiological detection, and particularly relates to a rapid escherichia coli test box which comprises a detection box, a sterile box, a multi-stage feeding device and a first motor, the first motor controls the working stroke of the multi-stage feeding device, and then the dosage of sterile water added into the sterile box is controlled; the farther the first motor is, the more sterile liquid is added into the sterile box, the smaller the dilution degree is, and the closer the first motor is, the less sterile liquid is added into the sterile box, and the larger the dilution degree is, so that the three sterile boxes are sequentially placed, and three diluents with different dilution degrees are obtained; the method does not need to manually separately use a sterilization suction tube to suck sterile water of different doses and add the sterile water into diluents of different diluents to obtain the diluents of different diluents, so that the detection time is greatly saved, and the detection efficiency is improved.

The invention relates to a bacteriophage, in particular to a cross-host multivalent bacteriophage and preparation and application of a bacteriostatic agent of the bacteriophage, the multivalent bacteriophage is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2026045. The salmonella bacteriophage CCTCC NO: M 2026045 is found for the first time, is a multivalent bacteriophage, can cross-host infect and split multiple important livestock and poultry intestinal pathogens such as salmonella, escherichia coli, shigella, klebsiella pneumoniae and proteus mirabilis, solves the problem of narrow host range of a single bacteriophage, and improves the prevention and control efficiency. By inhibiting the overgrowth of the gram-negative pathogenic bacteria, the intestinal microecological balance can be regulated, so that the aim of effective prevention and control is fulfilled.

The invention relates to the technical field of organic chemistry, and particularly discloses an amide derivative containing a thiazole oxime structure as shown in a general formula 8 and a preparation method and application of the amide derivative. The derivative shows remarkable antibacterial activity on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa and fluoroquinolone-resistant escherichia coli, particularly has a remarkable effect on gram-negative bacteria, has broad-spectrum antibacterial potential and can be used for preparing drugs for treating related bacterial infection, and the activity of part of compounds is superior to that of a control drug.

The invention relates to an antibacterial gel and a preparation method thereof. The gel mainly comprises silver ions, avocado oil, a radix puerariae extract, wheat germ oil, emulsifying wax, a folium artemisiae argyi extract, glycerol, a styrene / butadiene copolymer, purified water and hydroxyethyl cellulose. Extracts containing specific small-molecule polypeptides are extracted from Artemisia rubescens and Radix Puerariae through a specific extraction method, and the polypeptides are Artemisia rubescens polypeptides (SEQ ID No: 1) and Radix Puerariae polypeptides (SEQ ID No: 2) respectively. The extracts have a synergistic effect with silver ions, so that the antibacterial effect of the gel is remarkably improved, and particularly, the gel has a remarkable inhibiting effect on staphylococcus aureus, escherichia coli and candida albicans. The bacteriostatic gel is simple in preparation method, convenient to use and suitable for bacteriostasis of female vaginal mucosa and maintenance of vaginal micro-ecological internal environment.

The invention relates to a primer and probe combination for simultaneously detecting urinary tract klebsiella pneumoniae, escherichia coli and drug-resistant genes through nested PCR (Polymerase Chain Reaction) and a kit of the primer and probe combination, which are characterized in that a phoE target gene is selected for primer and probe design to ensure that cross amplification of related bacteria is not caused, so that the detection specificity requirement of actual klebsiella pneumoniae is met; the Klebsiella pneumoniae and the escherichia coli can be identified at the same time, the source of the drug-resistant gene KPC can be judged, and the method is very important for clinical precise diagnosis and treatment.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

This invention relates to an endogenous antimicrobial peptide from bovine milk and its applications. The antimicrobial polypeptide compound VAVALARPKHPIK is derived from endogenously enzymatically hydrolyzed bovine casein, with the amino acid sequence Val-Ala-Val-Ala-Leu-Ala-Arg-Pro-Lys-His-Pro-Ile-Lys. It exhibits broad inhibitory activity against both Gram-positive and Gram-negative bacteria, including *Porphyromonas gingivalis*, *Escherichia coli*, and *Staphylococcus aureus*. This antimicrobial peptide shows promising applications as a health supplement and / or medical device or pharmaceutical for the prevention and / or reduction of infectious diseases, as a food antimicrobial agent, in novel functional foods, pet food and animal feed additives, and in daily chemical products.

The application discloses a preparation method of E. coli extracellular vesicles and application of the E. coli extracellular vesicles in anti-breast cancer drugs. The preparation method of the E. coli extracellular vesicles comprises the following steps: knocking out a 3-dehydroquininase gene of E. coli to obtain a recombinant bacterium; lysing the recombinant bacterium and performing low-speed centrifugation to obtain a supernatant and a lysate; performing high-speed centrifugation on the lysate to obtain a precipitate, which is the E. coli extracellular vesicles. The E. coli extracellular vesicles prepared by the method can be applied to the preparation of anti-tumor drugs. The 3-dehydroquininase (aroD) gene of E. coli is singly knocked out to construct a recombinant bacterium strain, and OMVs extracted from the strain can directly inhibit the proliferation of HER2-negative Luminal A type breast cancer and triple-negative breast cancer, but the inhibiting effect on the proliferation of other subtypes of breast cancer is poor. The OMVs prepared by the application can provide a new path for the design and screening of anti-tumor drugs, and have a good drug-making prospect.

The application discloses a lipase mutant LipM1718, the amino acid sequence of the lipase mutant LipM1718 is shown as SEQ ID NO. 2, and the lipase mutant LipM1718 comprises eleven mutation sites of E61D, Q72N, N73A, P86A, N116A, A117P, I126V, Y134F, Q194R, A260I and S277T; the nucleotide sequence of a gene coding the lipase mutant LipM1718 is shown as SEQ ID NO. 1. The application constructs a recombinant carrier pET22b- LipM1718 containing the lipase mutant LipM1718, which is expressed in a prokaryotic host cell Escherichia coli BL21 (DE3). Experiment proves that the obtained lipase has high efficient catalytic activity of hydrolysis of ester substrates after the gene is expressed in the prokaryotic host cell, and has great application potential in the harmless treatment and resource utilization field of kitchen waste oil.

The invention relates to the technical field of water treatment materials, and discloses a nano-catalytic antibacterial filter material for a direct water dispenser, which comprises the following components in percentage by mass: 8-20% of broad-spectrum nano-antibacterial component, 55-85% of base material, 4-10% of binder, 2-5% of dispersant and 2-6% of assistant, the broad-spectrum nano antibacterial component is Ag-TiO / ZnO-CuO quaternary composite nanoparticles, and the mass ratio of Ag to TiO to ZnO to CuO is 1: (2-4): (1-3): (0.5-1.5). According to the nano catalytic antibacterial filter material and the preparation method thereof, the inhibition and killing rates on gram-negative bacteria (escherichia coli, pseudomonas aeruginosa and klebsiella pneumoniae), gram-positive bacteria (staphylococcus aureus, bacillus subtilis and methicillin-resistant staphylococcus aureus) and fungi (candida albicans and aspergillus niger) are all greater than or equal to 99.9%.

The present application relates to a kind of N-adamantyl benz [1,3] oxazin-2-ketone derivatives and its preparation method and application in antibacterial, belong to organic synthesis and application technical field.N-adamantyl benz [1,3] oxazin-2-ketone derivatives have as shown in structure general formula (I).Preparation method includes: with adamantylamine reduction Schiff base of guaiacol as raw material, with dichloromethane as reaction solvent, CDI is added, under reflux condition, the oxazinone product corresponding to the reduction Schiff base is prepared.Extract the reaction liquid with deionized water until the pH of organic phase is 7, dry, rotary evaporation, obtain target product.The present application applies N-adamantyl benz [1,3] oxazin-2-ketone derivatives to biological antibacterial, it is shown that staphylococcus aureus, escherichia coli, pseudomonas aeruginosa all have certain inhibitory effect.

The invention discloses a 2-(imidazo [1, 5-a] pyridine-1-yl)-1-methylpyridine-1-onium compound as well as a preparation method and an antibacterial and mildew-proof application thereof. The structural formula of the 2-(imidazo [1, 5-a] pyridine-1-yl)-1-methylpyridine-1-onium compound is shown as a formula (II), and the 2-(imidazo [1, 5-a] pyridine-1-yl)-1-methylpyridine-1-onium compound is easy to synthesize, shows good antibacterial and mildew-proof activity, has good antibacterial activity on staphylococcus aureus, escherichia coli, candida albicans and aspergillus fumigatus, serves as a novel antibacterial and mildew-proof agent, and has good application prospects. The method has great application value in the technical field of antibiosis. Formula (II)

The invention discloses an Escherichia coli bacteriophage D5, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D5 is CGMCC (China General Microbiological Culture Collection Center) NO. 46364, and the Escherichia coli bacteriophage D5 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D5 and other bacteriophages. The Escherichia coli phage D5 has good high temperature resistance and acid resistance, the environmental tolerance enables the Escherichia coli phage D5 to keep high activity and stability and high breeding speed in industrial production, and the Escherichia coli phage D5 is suitable for industrial production and supports rapid proliferation and large-scale fermentation production requirements; the compound has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a medicinal preparation or a disinfectant, and is applied to the aspects of sterilization, bacteriostasis and disinfection of the multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by the escherichia coli and the like.

The present application relates to the technical field of antibacterial coating, in particular to a processing method of triclosan antibacterial coating for suture, and the specific steps are as follows: S1, preparation of moxa tablet-triclosan antibacterial solution; S2, preparation of moxa tablet-triclosan spraying solution; S3, suture pretreatment; S4, suture spraying.The present application has the following beneficial effects: 1. Good versatility: the suture with moxa tablet-triclosan antibacterial coating prepared by the present application is sprayed by ultrasonic spraying machine, and the same production process is used for different suture materials and single or multi-strand sutures, so that the production cost is greatly reduced, and the development of enterprises is facilitated; 2. Broad-spectrum bacteriostasis: the suture has good bacteriostatic rate for staphylococcus aureus, escherichia coli and stenotrophomonas maltophilia; 3. Low allergenicity.

This invention relates to the field of biomedical technology and discloses a broad-spectrum antimicrobial peptide and its applications. The invention obtains a broad-spectrum antimicrobial peptide H by mining non-classical open reading frames (ncORFs) in the human genome. Experimental verification shows that the broad-spectrum antimicrobial peptide H has significant inhibitory effects on both Gram-positive bacteria (Staphylococcus aureus ATCC 29213) and Gram-negative bacteria (Escherichia coli K88). Furthermore, the broad-spectrum antimicrobial peptide H can form an α-helix. The α-helix structure projection diagram shows that one side is rich in positively charged hydrophilic amino acid residues, and the other side is rich in hydrophobic amino acid residues, exhibiting good amphiphilicity. In addition, the broad-spectrum antimicrobial peptide H provided by this invention has low hemolytic activity and no cytotoxicity, ensuring in vivo safety while achieving highly efficient bactericidal activity. It also features a short synthetic sequence, small molecular weight, and is easy to chemically synthesize.

The invention provides uridine kinase, a mutant thereof, a method for catalytically producing uridine monophosphate and application, and relates to the field of genetic engineering and microbial engineering. The uridine kinase CaUDK-T gene with the nucleotide sequence as shown in SEQ ID NO.1 is adopted, after escherichia coli is over-expressed, a substrate uridine is biologically catalyzed in combination with polyphosphate kinase PPK, and uridylic acid can be efficiently produced. Meanwhile, amino acid residues E148, S152 and V153 of uridine kinase CaUDK-T are replaced with glycine in a site-specific mutagenesis mode, mutants E148G, S152G and V153G are obtained through construction, the catalytic efficiency and conversion rate of uridine kinase are further improved, the enzyme activity of the uridine kinase mutant V153G is improved to 1.97 times that of wild enzyme, the conversion rate of 50 g / L uridine can reach 90%, efficient production of UMP is achieved, and the application prospect is wide. Therefore, the industrial production is promoted.

This invention provides an atypical tetracycline antibiotic derivative, its preparation method, and its application. The atypical tetracycline antibiotic derivative has the compound structure shown in Formula II: wherein, R 1’ Represents any one of H, amino group and its substituents or their hydrochloride salts, amine group, amide group, sulfonamide group, hydroxyl group and its substituents, and ester group; R 2’ Represents any one of H, alkyl, aryl, acyl, nitroso, amino, and amide. Based on a series of intermediates with structures shown in Formula I, this invention further synthesizes atypical tetracycline derivative structures with multiple site modifications. Cell activity tests show that they have varying degrees of inhibitory effects on *Escherichia coli* and *Staphylococcus aureus*, demonstrating potential for development into antibacterial therapies.

A microbial agent for fermenting low-nitrite, low-sodium sauerkraut and its preparation method include: *Leuconostoc mesenteriae* LM701 and *Lactobacillus plantarum* LP705, which have good nitrite degradation capabilities and effectively inhibit the growth of harmful bacteria such as *Escherichia coli*, *Staphylococcus aureus*, and *Salmonella* during sauerkraut fermentation. This enables low-sodium chloride fermentation, producing sauerkraut with a nitrite content ≤4 mg / kg and a crisp texture. The nitrite degradation rate of the fermented sauerkraut reaches over 63.8%. The nitrite content in the 1% edible salt concentration group is 2.69 mg / kg.

The invention discloses an antibacterial 10 peptide, which is characterized in that the sequence of the antibacterial 10 peptide is w-k-r-w-r-r-r-w-w-r-r (dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), and all amino acids are D-type amino acids. The antibacterial peptide provided by the invention has good antibacterial activity on various pathogenic bacteria, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and relatively good in-vivo antibacterial activity. The antibacterial peptide has broad-spectrum killing activity on multidrug-resistant acinetobacter baumannii, carbapenem-resistant pseudomonas aeruginosa and standard strains of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, methicillin-resistant staphylococcus aureus and staphylococcus aureus, and is low in hemolytic toxicity and high in killing activity. Under medium and low concentration (2 microgram / mL to 32 microgram / mL), the cell survival rate can reach more than half, and the cell culture medium has no toxic effect on cells, and is good in stability, strong in operability and low in cost.

This invention discloses the application of cinnamaldehyde as a potentiator for β-lactam antibiotics in inhibiting carbapenem-resistant Escherichia coli (CREC). The study confirms that cinnamaldehyde not only inhibits the growth of drug-resistant E. coli but also enhances the antibacterial activity of β-lactam antibiotics, effectively reducing the minimum inhibitory concentration (MIC) of meropenem and cefqinome against drug-resistant E. coli. Further research shows that high concentrations of cinnamaldehyde inhibit New Delhi metallo-β-lactamase-5 (NDM-5) enzyme. This discovery provides a new strategy for addressing the resistance of CREC to β-lactam antibiotics.

The application discloses a process for preparing ethanol by using cellulose pyrolysis liquid through electroactive escherichia coli, and belongs to the technical field of electrochemistry. In the application, waste cellulose is pyrolyzed and then pH is adjusted, a salt solution suitable for the growth of escherichia coli is prepared, and an antibiotic is added into a reaction system for fermentation and electrochemical conversion, and then the prepared escherichia coli reaction system is connected to an electrochemical system under sterile fermentation conditions to provide a micro-voltage. Through the above process, most of the internal ether sugar can be converted into ethanol, and the inhibitor in the pyrolysis liquid can be reduced by using an electric current, so that the degradation rate of the inhibitor is improved.

The invention relates to the technical field of organic chemistry, and particularly discloses an isoxazole amide derivative with a structure shown in a general formula III as well as a preparation method and application of the isoxazole amide derivative. The isoxazole amide derivative disclosed by the invention shows remarkable antibacterial activity on staphylococcus aureus, escherichia coli, methicillin-resistant staphylococcus aureus (MRSA) and fluoroquinolone-resistant escherichia coli (FREC), the activity of part of compounds is superior to that of gentamicin, and the isoxazole amide derivative has broad-spectrum antibacterial potential and can be used for preparing medicines for treating related bacterial infections.